Literature DB >> 15310608

Recent developments in thyroid eye disease.

Tom Cawood1, Paul Moriarty, Donal O'Shea.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15310608      PMCID： PMC509348          DOI： 10.1136/bmj.329.7462.385

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  26 in total

Review 1.  Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Authors:  Bellur S Prabhakar; Rebecca S Bahn; Terry J Smith
Journal:  Endocr Rev       Date:  2003-12       Impact factor: 19.871

2.  Genetics of thyroid-associated ophthalmopathy: a play in search of a cast of characters.

Authors:  N R Farid; M Marga
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

3.  Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association.

Authors:  S C Werner
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

Review 4.  Pathogenesis of Graves' ophthalmopathy.

Authors:  R S Bahn; A E Heufelder
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

5.  The spectrum of thyroid disease in a community: the Whickham survey.

Authors:  W M Tunbridge; D C Evered; R Hall; D Appleton; M Brewis; F Clark; J G Evans; E Young; T Bird; P A Smith
Journal:  Clin Endocrinol (Oxf)       Date:  1977-12       Impact factor: 3.478

6.  Impact of smoking on the response to treatment of thyroid associated ophthalmopathy.

Authors:  A Eckstein; B Quadbeck; G Mueller; A W Rettenmeier; R Hoermann; K Mann; P Steuhl; J Esser
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

7.  Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.

Authors:  P Perros; A L Crombie; J N Matthews; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1993-04       Impact factor: 3.478

8.  Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?

Authors:  Kerry Starkey; Armin Heufelder; Glynn Baker; Werner Joba; Marc Evans; Stephen Davies; Marian Ludgate
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

Review 9.  Emergency treatment of Graves' ophthalmopathy.

Authors:  R S Bahn; G B Bartley; C A Gorman
Journal:  Baillieres Clin Endocrinol Metab       Date:  1992-01

10.  A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.

Authors:  Mark F Prummel; Caroline B Terwee; Martin N Gerding; Lelio Baldeschi; Maarten P Mourits; Leo Blank; Friedo W Dekker; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958
View more
  15 in total

Review 1.  Diagnosis and management of thyrotoxicosis.

Authors:  Elizabeth N Pearce
Journal:  BMJ       Date:  2006-06-10

2.  Asymmetric ophthalmopathy in a hypothyroid patient.

Authors:  Taryn Taylor; Charles Czarnowski
Journal:  Can Fam Physician       Date:  2007-04       Impact factor: 3.275

3.  Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.

Authors:  George Saraci; Anamaria Treta
Journal:  Maedica (Buchar)       Date:  2011-04

4.  [Clinical and neuroradiological diagnostics in Graves' orbitopathy].

Authors:  F Beisse; C Pieh-Beisse; W A Lagrèze; C Hader
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

Review 5.  Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Yasmin Shayesteh; Walter M Jay
Journal:  Neuroophthalmology       Date:  2015-06-17

6.  Endonasal bilateral simultaneous orbital decompression.

Authors:  A Tsikoudas; G Thiel; E Blenke; G McDougall
Journal:  Hippokratia       Date:  2006-10       Impact factor: 0.471

Review 7.  Management of thyroid disorders.

Authors:  L D K E Premawardhana; J H Lazarus
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

8.  Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy.

Authors:  Chu Zhang; Xianfeng Zhang; Lizhen Ma; Fengying Peng; Jiao Huang; Hui Han
Journal:  Endocrine       Date:  2012-01-12       Impact factor: 3.633

9.  Does thyroid surgery for Graves' disease improve health-related quality of life?

Authors:  Gregorio Scerrino; Giuditta Morfino; Nunzia Cinzia Paladino; Valentina Di Paola; Emanuele Amodio; Gaspare Gulotta; Sebastiano Bonventre
Journal:  Surg Today       Date:  2012-12-11       Impact factor: 2.549

10.  Description and evaluation of the first national patient and public involvement day for thyroid eye disease in the United Kingdom.

Authors:  Henry B Smith; Carol Porteous; Catey Bunce; Karen Bonstein; Janis Hickey; Colin M Dayan; Gill Adams; Geoff E Rose; Daniel G Ezra
Journal:  Thyroid       Date:  2014-07-21       Impact factor: 6.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.